In breast cancer, febrile neutropenia-related admissions account for significant mortality

Share this content:

the ONA take:

According to a new study published in the journal Supportive Care in Cancer, researchers from the Reading Health System Department of Internal Medicine in West Reading, Pennsylvania, have found that febrile neutropenia-related hospitalizations still account for significant health care resource use, morbidity, and mortality among patients with breast cancer.

For the retrospective study, researchers sought to investigate the mean length of stay, incidence of morbidity and mortality, and health care costs associated with febrile neutropenia-related admissions of patients with breast cancer.

Researchers identified patients with breast cancer who were hospitalized for febrile neutropenia between 2009 and 2011 from the Nationwide Impact Sample database. Results showed that the mean length of stay was 5.7 days (95% CI: 5.5 - 5.9) and the mean cost of hospitalization was $37,087 (95% CI: 34,009 - 40,165).

They found that the average inhospital mortality rate during that period was 2.6% (n = 685), and age 65 years and older was associated with a higher risk of mortality (4.4% vs 1.7%; OR = 2.7; 95% CI: 2.3 - 3.1; P < 0.01). The findings suggest that febrile neutropenia accounts for significant mortality, and more effort needs to be made to reduce the cost of health care without decreasing the quality of care.

Cultured circulating tumor cells reveal genetic profile of breast cancer cells
Febrile neutropenia-related hospitalizations still account for morbidity, and mortality among patients with breast cancer.
Febrile neutropenia–related hospitalizations continue to account for significant morbidity, mortality, and health care resource utilization among patients with breast cancer. Further efforts should be focused on curtailing the rising health care costs without compromising the quality of care.
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs